1. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial;Gallant;Lancet,2017
2. HHS Panel on Antiretroviral Guidelines for Adults and Adolescents 2018 Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
3. Lazerwith , S. E. Cai , R. Chen , X. Chin , G. Desai , M. C. Eng , S. Jin , H. 2016 Discovery of bictegravir (GS-9883), a novel, unboosted, once-daily HIV-1 integrase strand transfer inhibitor (INSTI) with improved pharmacokinetics and In Vitro Resist Profile http://www.natap.org/2016/HIV/062016_05.htm
4. An enhanced emtricitabine-loaded long-acting nanoformulation for prevention or treatment of HIV infection;Mandal;Antimicrobial Agents and Chemotherapy,2017
5. Long-acting parenteral combination antiretroviral loaded nano-drug delivery system to treat chronic HIV-1 infection: A humanized mouse model study;Mandal;Antiviral Research,2018